NCT05797987View on ClinicalTrials.gov

Negative ER Expression Assessed by 18F-FES PET/CT in the MBC With ER-positive Primary Tumor

CompletedOBSERVATIONAL
Enrollment

52

Participants

Timeline

Start Date

December 1, 2022

Primary Completion Date

August 1, 2023

Study Completion Date

August 1, 2023

Conditions
Breast Cancer
Trial Locations (1)

200032

Biyun Wang, MD, Shanghai

All Listed Sponsors
lead

Fudan University

OTHER